AltruBio
Los Altos
About AltruBio
AltruBio is focused on developing targeted antibody therapeutics for the treatment of cancer and immune-related inflammatory diseases. AltruBio International in Delaware with principal office in SFO Bay Area California is a biopharmaceutical company integrated globally and virtually to develop targeted antibody therapeutics for the treatment of cancer and immune-related inflammatory diseases. With its R&D foundation in Taipei Taiwan since June 2000, AbGenomics has been focusing on the discovery and development of novel therapeutics for unmet medical needs. Their R&D scientists built an efficient discovery platform to identify and validate novel antibody therapeutics. Currently, AbGenomics has several potential therapeutic antibodies targeting autoimmune diseases, pancreatic cancer, stomach cancer, colorectal cancer, ovarian cancer, lung cancer, and other solid tumors in various development stages.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Total funding: $327.6M
- Funding stage: Early Stage Venture
- Last round: Series B (May 2024)
- Website: altrubio.com
- Phone: (650) 988-9912
Industries & Categories
Biotechnology, Health Care, Medical
Social Profiles
Canonical: https://fsome.com/organization/altrubio-6470 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.